Prostate cancer update: 2006

Current Opinion in Oncology

Volumn 19, Issue 3, 2007, Pages 229-233

  Lin, Amy M ^a   Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemoprevention; Hormonal therapy; Immunotherapy; Prostate cancer; Screening

Indexed keywords

ELLAGIC ACID; FINASTERIDE; GONADORELIN AGONIST; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PROVENGE;

APOPTOSIS; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER LOCALIZATION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; DIABETES MELLITUS; HEART INFARCTION; HUMAN; IMMUNOTHERAPY; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SUDDEN DEATH; TREATMENT FAILURE;

CHEMOPREVENTION; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 34247155343     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3280ad43bd     Document Type: Review

References (24)

1. Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA 2006; 296:2336-2342. This study highlights the frequent PSA screening practices in elderly men despite the lack of definitive screening guidelines.
2. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215-224.
3. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006; 98:1128-1133. This study demonstrates that finasteride used as a chemoprevention agent may increase sensitivity of PSA to detect prostate cancer and may not actually increase the risk of developing high-grade prostate cancer.
4. Lin DW, Coleman IM, Hawley S, et al. Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. J Clin Oncol 2006; 24:3763-3770.
5. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351:125-135.
6. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005; 294:440-447.
7. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006; 98:1521-1527.
8. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006; 24:1990-1996.
9. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Institute 2003; 95:981-989.
10. Shahinian VB, Kuo YF, Freeman JL, et al. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005; 103:1615-1624.
11. Kawakami J, Cowan JE, Elkin EP, et al. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 2006; 106:1708-1714.
12. Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006; 24:1868-1876. Immediate ADT offers a small, but significant overall survival advantage over ADT administered at the time of symptomatic progression. This study adds to the body of literature suggesting that earlier ADT may be appropriate.
13. D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292:821-827.
14. D'Amico AV, Loffredo M, Renshaw AA, et al. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. J Clin Oncol 2006; 24:4190-4195. Patients with a high PSA velocity prior to definitive local radiotherapy may benefit from addition of a short course of ADT.
15. Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296:2329-2335. Adjuvant radiotherapy does not prolong survival in patients with high-risk localized prostate cancer but may prolong time to use of ADT.
16. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366:572-578.
17. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7:472-479.
18. Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006; 24:3973-3978. A standard definition of biochemical relapse following prostatectomy that predicts relevant clinical outcomes will help standardize outcomes reporting for trials.
19. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65:965-974. The new Phoenix definition of biochemical failure following radiotherapy corrects for several of the shortcomings of the original ASTRO definition and takes into account use of ADT which is being used more frequently with radiation therapy.
20. Pantuck AJ, Leppert JT, Zomorodian N, et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 2006; 12:4018-4026. This is one of the first trials to demonstrate a modulation of PSA kinetics with a nutritional/dietary intervention.
21. Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006; 24:3984-3990. This is the first study to demonstrate that PSA kinetics and depth of PSA nadir is associated with survival in men with metastatic prostate cancer who have initiated ADT.
22. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24:4448-4456. This is the first study to demonstrate the association of ADT and increased cardiovascular and diabetic risk, indicating that more selective use of ADT may be warranted.
23. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the 'androgen deprivation syndrome' in men receiving androgen deprivation for prostate cancer. Arch Intern Med 2006; 166:465-471.
24. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089-3094. Sipuleucel-T is the first immunotherapy regimen for prostate cancer that may be associated with improved overall survival.